source
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.BioPharma Dive · 14d ago↗ source
- ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancerSac-TMT significantly extended overall and progression-free survival for patients with advanced or recurrent endometrial cancer by 6.9 months over chemotherapy in a Phase 3 trial—becoming the first…BioSpace · 14d ago↗ source
- STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and moreBristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial